Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 11/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 8/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.58 |
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | USP2 | O75604 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAK | O14976 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114664 | 0.88 | CYP1A2 (0.54) | CYP3A4CLK4CYP1A2MAPK1LMNA | |
| SCHEMBL3122430 | 0.84 | CYP3A4 (0.57) | CYP3A4CLK4CYP1A2MAPK1LMNA | |
| SCHEMBL4351394 | 0.79 | CYP3A4 (0.70) | CYP3A4CLK4CYP1A2MAPK1LMNA | |
| SCHEMBL4357245 | 0.79 | CLK4 (0.70) | CYP3A4CLK4CYP1A2MAPK1LMNA | |
| SCHEMBL19398319 | 0.79 | IRAK4 (0.59) | CYP3A4CLK4CYP1A2MAPK1LMNA | |
| SCHEMBL12927745 | 0.78 | CLK4 (0.61) | CYP3A4CLK4CYP1A2MAPK1LMNA | |
| SCHEMBL3119211 | 0.78 | CLK4 (0.62) | CYP3A4CLK4CYP1A2MAPK1LMNA | |
| SCHEMBL3124790 | 0.78 | CLK4 (0.65) | CYP3A4CLK4CYP1A2MAPK1LMNA | |
| SCHEMBL14642234 | 0.77 | LRRK2 (0.50) | CYP3A4CLK4CYP1A2MAPK1LMNA | |
| SCHEMBL3116591 | 0.77 | CLK4 (0.64) | CYP3A4CLK4CYP1A2MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2167092-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| WO-2008157191-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, AKT3 | CYP3A4 2163/4885CLK4 1312/4885CYP1A2 3179/4885 |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, AKT3 | CYP3A4 2163/4885CLK4 1312/4885CYP1A2 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.